Nebula Research & Development LLC Cullinan Oncology, Inc. Transaction History

Nebula Research & Development LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$7.13 - $9.08 $82,380 - $104,910	-11,554 Reduced 26.62%	31,853 $240 Million
Q1 2025 May 15, 2025	SELL	$7.57 - $12.68 $2,233 - $3,740	-295 Reduced 0.68%	43,407 $329 Million
Q4 2024 Feb 14, 2025	BUY	$10.77 - $17.6 $98,707 - $161,304	9,165 Added 26.54%	43,702 $532 Million
Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.86 $343,234 - $446,654	21,412 Added 163.14%	34,537 $578 Million
Q2 2024 Aug 14, 2024	SELL	$15.63 - $29.35 $180,182 - $338,346	-11,528 Reduced 46.76%	13,125 $229 Million
Q1 2024 May 15, 2024	BUY	$10.17 - $19.02 $250,721 - $468,900	24,653 New	24,653 $420 Million

149

65.1M

10.7K

14.4K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $390M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

Stay updated on Nebula Research & Development LLC with notifications on news.